Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
NYS Entity Status
NYS Filing Date
FEBRUARY 12, 2013
NYS DOS ID#
NATIONAL CORPORATE RESEARCH, LTD.
10 EAST 40TH STREET 10TH FLOOR
NEW YORK, NEW YORK, 10016
NYS Entity Type
FOREIGN LIMITED LIABILITY COMPANY
2013 - GIL, GPS & RHM, LLC
Around the Web
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- Fit City: Taking Night-Life Cue, Gyms Lower the Lights
By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017
Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.
- Phil Jackson will go down with the worst execs in NYC sports
By Zach Braziller - Thursday Jun 29, 2017
Was Phil Jackson the worst executive in New York Sports history? Here are some of the other candidates: M. Donald Grant Mets Chairman of the Board, 1962-78 Grant is credited for hiring Gil Hodges as manager in 1968, and the Miracle Mets won the World Series the next season. His watch included another NL pennant...
- Odell Beckham getting new-age treatment on injured ankle
By Fred Kerber, Mark Hale - Friday Aug 25, 2017
Odell Beckham Jr. is availing himself of some modern medicine in an attempt to heal his injured left ankle. Beckham, according to NFL.com’s and SiriusXM’s Gil Brandt, is beginning Phoenix Thera-Lase cell treatment on Friday. The treatment’s website claims that Thera-Lase “is a non-invasive, drug free laser therapy treatment which provides relief and healing for...
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]